Induction of Apoptosis in Human Oral Keratinocyte by Doxorubicin
Overview
Authors
Affiliations
Background/aim: We have previously reported that doxorubicin (DXR) showed much higher cytotoxicity against human oral squamous cell carcinoma cell lines compared to normal human mesenchymal normal oral cells (gingival fibroblast, periodontal ligament fibroblast, pulp cell), yielding high tumor-specificity. However, we unexpectedly found that doxorubicin showed potent cytotoxicity against human normal oral keratinocytes and primary gingival epithelial cells. In the present study, we investigated the reproducibility, underlining mechanisms and generality of this unexpected finding.
Materials And Methods: Viable cell number was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method, fine cell structure by transmission electron microscopy and apoptosis induction by western blot analysis.
Results: Doxorubicin induced keratinocyte toxicity, regardless of cell density and concentration of FBS in the culture medium. Doxorubicin induced apoptosis (characterized by the loss of cell surface microvilli, chromatin condensation, nuclear fragmentation and caspase-3 activation) in keratinocytes. A total of 11 anticancer drugs showed similar keratinocyte toxicity. Alkaline extract of the leaves of Sasa senanensis Rehder partially alleviated the DXR-induced keratinocyte cytotoxicity by promoting cell growth.
Conclusion: The present study suggested that oral keratinocyte toxicity is a novel adverse effect of most anticancer agents.
Orabi M, Orabi E, Abdullah Al Awadh A, Alshahrani M, Abdel-Wahab B, Sakagami H Antioxidants (Basel). 2023; 12(11).
PMID: 38001804 PMC: 10669829. DOI: 10.3390/antiox12111951.
Abe T, Sakagami H, Amano S, Uota S, Bandow K, Uesawa Y Medicines (Basel). 2023; 10(7).
PMID: 37505064 PMC: 10386476. DOI: 10.3390/medicines10070043.
Prominent Anti-UVC Activity of Lignin Degradation Products.
Sakagami H, Amano S, Uota S, Tanuma S, Inomata M, Shindo A In Vivo. 2022; 36(6):2689-2699.
PMID: 36309360 PMC: 9677805. DOI: 10.21873/invivo.13004.
Identification of therapeutically potential targets and their ligands for the treatment of OSCC.
Kumari P, Kumar S, Sethy M, Bhue S, Mohanta B, Dixit A Front Oncol. 2022; 12:910494.
PMID: 36203433 PMC: 9530560. DOI: 10.3389/fonc.2022.910494.
Naitoh K, Orihara Y, Sakagami H, Miura T, Satoh K, Amano S Int J Mol Sci. 2022; 23(5).
PMID: 35269748 PMC: 8910578. DOI: 10.3390/ijms23052601.